Search

Your search keyword '"Musto, Pellegrino"' showing total 2,683 results

Search Constraints

Start Over You searched for: Author "Musto, Pellegrino" Remove constraint Author: "Musto, Pellegrino"
2,683 results on '"Musto, Pellegrino"'

Search Results

152. IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective

153. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

154. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

155. Pyridine Controlled Tin Perovskite Crystallization

156. Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma

157. Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients

158. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy

160. Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group

161. JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

162. OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial

163. P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma

165. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

167. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

171. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

173. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders

174. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study

175. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

178. Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

179. Clonal hematopoiesis in clinical practice: walking a tightrope

181. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

182. Exploring the Potential of Eltrombopag: Room for More?

186. Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia

187. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

189. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

191. Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials

192. Sorption of CO 2 , CH 4 and Their Mixtures in Amorphous Poly(2,6-dimethyl-1,4-phenylene)oxide (PPO).

193. RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.

197. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

200. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation

Catalog

Books, media, physical & digital resources